UK medicines regulators are moving to withdraw the controversial vasculitis drug Tavneos after concerns over unreliable trial data, adding fresh pressure to a treatment that has already faced scrutiny in the United States and Europe.
The Medicines and Healthcare products Regulatory Agency has said it plans to pull the drug, also known as avacopan, from the market following questions about the evidence supporting its use in ANCA-associated vasculitis. The condition includes granulomatosis with polyangiitis and microscopic polyangiitis, both serious diseases that cause inflammation of small blood vessels.
Why the decision matters for patients with rare vasculitis
Tavneos was approved in 2021 for patients with severe active ANCA-associated vasculitis, offering a treatment option for a rare and potentially life-threatening disease. But the drug has been under sustained review after the US Food and Drug Administration identified evidence that trial data had been manipulated, and the European Medicines Agency recently recommended revoking its marketing authorisation.
A crucial study that helped support the drug’s approval was retracted by the New England Journal of Medicine, intensifying doubts over the integrity of the underlying evidence. That sequence of events has left the future of Tavneos in doubt and raised questions about how regulators respond when the safety and reliability of pivotal studies come under fire.
Regulatory scrutiny continues across the UK, US and Europe
The BMJ reported that the FDA has also identified cases of serious liver injury in patients taking Tavneos for severe active ANCA-associated vasculitis, further complicating the risk-benefit picture for clinicians and patients. In the UK, the latest move reflects a cautious approach to a medicine that was developed for a rare disease but is now surrounded by uncertainty.
For people living with vasculitis, the situation underscores the importance of dependable clinical evidence and post-approval monitoring. When a treatment for a serious condition is challenged on data integrity grounds, regulators must weigh the need for access against the possibility that the evidence base no longer supports continued use.
As the review unfolds, clinicians treating ANCA-associated vasculitis will be watching closely for guidance on alternative management strategies and any formal decision on the drug’s future availability in the UK. The case also serves as another reminder that even approved medicines can face reversal when the foundation behind them is called into question.
Source material: The BMJ report on Tavneos
Photo source: AI-generated or edited image
